CXCL10 and non-small cell lung carcinoma: We have previously shown that activation of the STING pathway, as suggested by increased gene expression for CCL5 and CXCL10, two specific STING effector chemokines, identifies a subgroup of immune checkpoint inhibitor responsive NSCLC patients [11].